Clinical characteristics and immune profiles of patients with immune-mediated alopecia associated with COVID-19 vaccinations

Clinical characteristics and immune profiles of patients with immune-mediated alopecia associated with COVID-19 vaccinations

Copyright © 2023. Published by Elsevier Inc.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 255(2023) vom: 01. Okt., Seite 109737
1. Verfasser: Wang, Chuang-Wei (VerfasserIn)
Weitere Verfasser: Wu, Ming-Ying, Chen, Chun-Bing, Lin, Wei-Chen, Wu, Jennifer, Lu, Chun-Wei, Chen, Wei-Ti, Wang, Fang-Ying, Hui, Rosaline Chung-Yee, Chi, Min-Hui, Chiu, Tsu-Man, Chang, Ya-Ching, Lin, Jing Yi, Lin, Yang Yu-Wei, Tsai, Wan-Ting, Hung, Shuen-Iu, Chung, Wen-Hung
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2023
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Alopecia areata Autoimmune disease COVID-19 vaccine Granulysin Lymphocyte activation test Polyethylene glycol Spike protein COVID-19 Vaccines mehr... Spike Glycoprotein, Coronavirus spike protein, SARS-CoV-2
LEADER 01000caa a22002652c 4500
001 NLM360858708
003 DE-627
005 20250305043355.0
007 cr uuu---uuuuu
008 231226s2023 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2023.109737  |2 doi 
028 5 2 |a pubmed25n1202.xml 
035 |a (DE-627)NLM360858708 
035 |a (NLM)37586672 
035 |a (PII)S1521-6616(23)00500-4 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Wang, Chuang-Wei  |e verfasserin  |4 aut 
245 1 0 |a Clinical characteristics and immune profiles of patients with immune-mediated alopecia associated with COVID-19 vaccinations 
264 1 |c 2023 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 02.10.2023 
500 |a Date Revised 02.10.2023 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2023. Published by Elsevier Inc. 
520 |a BACKGROUND: The clinical characteristics and pathomechanism for immune-mediated alopecia following COVID-19 vaccinations are not clearly characterized 
520 |a OBJECTIVE: We investigated the causality and immune mechanism of COVID-19 vaccines-related alopecia areata (AA) 
520 |a STUDY DESIGN: 27 new-onset of AA patients after COVID-19 vaccinations and 106 vaccines-tolerant individuals were enrolled from multiple medical centers for analysis 
520 |a RESULTS: The antinuclear antibody, total IgE, granulysin, and PARC/CCL18 as well as peripheral eosinophil count were significantly elevated in the patients with COVID-19 vaccines-related AA compared with those in the tolerant individuals (P = 2.03 × 10-5-0.039). In vitro lymphocyte activation test revealed that granulysin, granzyme B, and IFN-γ released from the T cells of COVID-19 vaccines-related AA patients could be significantly increased by COVID-19 vaccine excipients (polyethylene glycol 2000 and polysorbate 80) or spike protein (P = 0.002-0.04) 
520 |a CONCLUSIONS: Spike protein and excipients of COVID-19 vaccines could trigger T cell-mediated cytotoxicity, which contributes to the pathogenesis of immune-mediated alopecia associated with COVID-19 vaccines 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Alopecia areata 
650 4 |a Autoimmune disease 
650 4 |a COVID-19 vaccine 
650 4 |a Granulysin 
650 4 |a Lymphocyte activation test 
650 4 |a Polyethylene glycol 
650 4 |a Spike protein 
650 7 |a COVID-19 Vaccines  |2 NLM 
650 7 |a Spike Glycoprotein, Coronavirus  |2 NLM 
650 7 |a spike protein, SARS-CoV-2  |2 NLM 
700 1 |a Wu, Ming-Ying  |e verfasserin  |4 aut 
700 1 |a Chen, Chun-Bing  |e verfasserin  |4 aut 
700 1 |a Lin, Wei-Chen  |e verfasserin  |4 aut 
700 1 |a Wu, Jennifer  |e verfasserin  |4 aut 
700 1 |a Lu, Chun-Wei  |e verfasserin  |4 aut 
700 1 |a Chen, Wei-Ti  |e verfasserin  |4 aut 
700 1 |a Wang, Fang-Ying  |e verfasserin  |4 aut 
700 1 |a Hui, Rosaline Chung-Yee  |e verfasserin  |4 aut 
700 1 |a Chi, Min-Hui  |e verfasserin  |4 aut 
700 1 |a Chiu, Tsu-Man  |e verfasserin  |4 aut 
700 1 |a Chang, Ya-Ching  |e verfasserin  |4 aut 
700 1 |a Lin, Jing Yi  |e verfasserin  |4 aut 
700 1 |a Lin, Yang Yu-Wei  |e verfasserin  |4 aut 
700 1 |a Tsai, Wan-Ting  |e verfasserin  |4 aut 
700 1 |a Hung, Shuen-Iu  |e verfasserin  |4 aut 
700 1 |a Chung, Wen-Hung  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 255(2023) vom: 01. Okt., Seite 109737  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnas 
773 1 8 |g volume:255  |g year:2023  |g day:01  |g month:10  |g pages:109737 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2023.109737  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 255  |j 2023  |b 01  |c 10  |h 109737